

Senate
Study
Bill
1115
-
Introduced


SENATE
FILE
_____


BY
(PROPOSED
COMMITTEE


ON
COMMERCE
BILL
BY


CHAIRPERSON
ANDERSON)


A
BILL
FOR


An
Act
relating
to
the
use
of
experimental
treatments
for
1


patients
with
a
terminal
illness.
2


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
3


TLSB
1882XC
(1)
87


tr/nh



S.F.
_____


Section
1.
NEW
SECTION
.
144E.1
Title.
1


This
chapter
shall
be
known
and
may
be
cited
as
the
“Right
2


to
Try
Act”
.
3


Sec.
2.
NEW
SECTION


.
144E.2
Definitions.
4


As
used
in
this
chapter:
5


1.
“Eligible
patient”
means
an
individual
who
meets
all
of
6


the
following
conditions:
7


a.
Has
a
terminal
illness,
attested
to
by
the
patient’s
8


treating
physician.
9


b.
Has
considered
and
rejected
or
has
tried
and
failed
to
10


respond
to
all
other
treatment
options
approved
by
the
United
11


States
food
and
drug
administration.
12


c.
Has
received
a
recommendation
from
the
individual’s
13


physician
for
an
investigational
drug,
biological
product,
or
14


device.
15


d.
Has
given
written
informed
consent
for
the
use
of
the
16


investigational
drug,
biological
product,
or
device.
17


e.
Has
documentation
from
the
individual’s
physician
that
18


the
individual
meets
the
requirements
of
this
subsection.
19


2.
“Investigational
drug,
biological
product,
or
device”
20


means
a
drug,
biological
product,
or
device
that
has
21


successfully
completed
phase
1
of
a
United
States
food
and
drug
22


administration-approved
clinical
trial
but
has
not
yet
been
23


approved
for
general
use
by
the
United
States
food
and
drug
24


administration
and
remains
under
investigation
in
a
United
25


States
food
and
drug
administration-approved
clinical
trial.
26


3.
“Terminal
illness”
means
a
progressive
disease
or
medical
27


or
surgical
condition
that
entails
significant
functional
28


impairment,
that
is
not
considered
by
a
treating
physician
to
29


be
reversible
even
with
administration
of
treatments
approved
30


by
the
United
States
food
and
drug
administration,
and
that,
31


without
life-sustaining
procedures,
will
result
in
death.
32


4.
“Written
informed
consent”
means
a
written
document
that
33


is
signed
by
the
patient,
a
parent
of
a
minor
patient,
or
a
34


legal
guardian
or
other
legal
representative
of
the
patient
and
35


-1-


LSB
1882XC
(1)
87


tr/nh
1/
6





S.F.
_____


attested
to
by
the
patient’s
treating
physician
and
a
witness
1


and
that
includes
all
of
the
following:
2


a.
An
explanation
of
the
products
and
treatments
approved
by
3


the
United
States
food
and
drug
administration
for
the
disease
4


or
condition
from
which
the
patient
suffers.
5


b.
An
attestation
that
the
patient
concurs
with
the
6


patient’s
treating
physician
in
believing
that
all
products
7


and
treatments
approved
by
the
United
States
food
and
drug
8


administration
are
unlikely
to
prolong
the
patient’s
life.
9


c.
Clear
identification
of
the
specific
proposed
10


investigational
drug,
biological
product,
or
device
that
the
11


patient
is
seeking
to
use.
12


d.
A
description
of
the
best
and
worst
potential
outcomes
13


of
using
the
investigational
drug,
biological
product,
or
14


device
and
a
realistic
description
of
the
most
likely
outcome.
15


The
description
shall
include
the
possibility
that
new,
16


unanticipated,
different,
or
worse
symptoms
might
result
17


and
that
death
could
be
hastened
by
use
of
the
proposed
18


investigational
drug,
biological
product,
or
device.
The
19


description
shall
be
based
on
the
treating
physician’s
20


knowledge
of
the
proposed
investigational
drug,
biological
21


product,
or
device
in
conjunction
with
an
awareness
of
the
22


patient’s
condition.
23


e.
A
statement
that
the
patient’s
health
plan
or
third-party
24


administrator
and
provider
are
not
obligated
to
pay
for
any
25


care
or
treatments
consequent
to
the
use
of
the
investigational
26


drug,
biological
product,
or
device,
unless
they
are
27


specifically
required
to
do
so
by
law
or
contract.
28


f.
A
statement
that
the
patient’s
eligibility
for
hospice
29


care
may
be
withdrawn
if
the
patient
begins
curative
treatment
30


with
the
investigational
drug,
biological
product,
or
device
31


and
that
care
may
be
reinstated
if
this
treatment
ends
and
the
32


patient
meets
hospice
eligibility
requirements.
33


g.
A
statement
that
the
patient
understands
that
the
34


patient
is
liable
for
all
expenses
consequent
to
the
use
of
35


-2-


LSB
1882XC
(1)
87


tr/nh
2/
6



S.F.
_____


the
investigational
drug,
biological
product,
or
device
and
1


that
this
liability
extends
to
the
patient’s
estate
unless
2


a
contract
between
the
patient
and
the
manufacturer
of
the
3


investigational
drug,
biological
product,
or
device
states
4


otherwise.
5


Sec.
3.
NEW
SECTION


.
144E.3
Manufacturer
rights.
6


1.
A
manufacturer
of
an
investigational
drug,
biological
7


product,
or
device
may
make
available
and
an
eligible
patient
8


may
request
the
manufacturer’s
investigational
drug,
biological
9


product,
or
device
under
this
chapter.
This
chapter
does
not
10


require
a
manufacturer
of
an
investigational
drug,
biological
11


product,
or
device
to
provide
or
otherwise
make
available
the
12


investigational
drug,
biological
product,
or
device
to
an
13


eligible
patient.
14


2.
A
manufacturer
described
in
subsection
1
may
do
any
of
15


the
following:
16


a.
Provide
an
investigational
drug,
biological
product,
or
17


device
to
an
eligible
patient
without
receiving
compensation.
18


b.
Require
an
eligible
patient
to
pay
the
costs
of,
or
the
19


costs
associated
with,
the
manufacture
of
the
investigational
20


drug,
biological
product,
or
device.
21


Sec.
4.
NEW
SECTION


.
144E.4
Treatment
coverage.
22


1.
This
chapter
does
not
expand
the
coverage
required
of
an
23


insurer
under
Title
XIII,
subtitle
1.
24


2.
A
health
plan,
third-party
administrator,
or
25


governmental
agency
may
provide
coverage
for
the
cost
of
an
26


investigational
drug,
biological
product,
or
device,
or
the
27


cost
of
services
related
to
the
use
of
an
investigational
drug,
28


biological
product,
or
device
under
this
chapter.
29


3.
This
chapter
does
not
require
any
governmental
agency
30


to
pay
costs
associated
with
the
use,
care,
or
treatment
of
a
31


patient
with
an
investigational
drug,
biological
product,
or
32


device.
33


4.
This
chapter
does
not
require
a
hospital
licensed
under
34


chapter
135B
or
other
health
care
facility
to
provide
new
or
35


-3-


LSB
1882XC
(1)
87


tr/nh
3/
6





S.F.
_____


additional
services.
1


Sec.
5.
NEW
SECTION


.
144E.5
Heirs
not
liable
for
treatment
2


debts.
3


If
a
patient
dies
while
being
treated
by
an
investigational
4


drug,
biological
product,
or
device,
the
patient’s
heirs
are
5


not
liable
for
any
outstanding
debt
related
to
the
treatment
6


or
lack
of
insurance
due
to
the
treatment,
unless
otherwise
7


required
by
law.
8


Sec.
6.
NEW
SECTION


.
144E.6
Provider
recourse.
9


1.
To
the
extent
consistent
with
state
law,
the
board
of
10


medicine
created
under
chapter
147
shall
not
revoke,
fail
11


to
renew,
suspend,
or
take
any
action
against
a
physician’s
12


license
based
solely
on
the
physician’s
recommendations
to
13


an
eligible
patient
regarding
access
to
or
treatment
with
an
14


investigational
drug,
biological
product,
or
device.
15


2.
To
the
extent
consistent
with
federal
law,
an
entity
16


responsible
for
Medicare
certification
shall
not
take
action
17


against
a
physician’s
Medicare
certification
based
solely
on
18


the
physician’s
recommendation
that
a
patient
have
access
to
an
19


investigational
drug,
biological
product,
or
device.
20


Sec.
7.
NEW
SECTION


.
144E.7
State
interference.
21


An
official,
employee,
or
agent
of
this
state
shall
not
22


block
or
attempt
to
block
an
eligible
patient’s
access
to
23


an
investigational
drug,
biological
product,
or
device.
24


Counseling,
advice,
or
a
recommendation
consistent
with
medical
25


standards
of
care
from
a
licensed
physician
is
not
a
violation
26


of
this
section.


27


Sec.
8.
NEW
SECTION
.
144E.8
Private
cause
of
action.
28


1.
This
chapter
shall
not
create
a
private
cause
of
29


action
against
a
manufacturer
of
an
investigational
drug,
30


biological
product,
or
device
or
against
any
other
person
31


or
entity
involved
in
the
care
of
an
eligible
patient
using
32


the
investigational
drug,
biological
product,
or
device
33


for
any
harm
done
to
the
eligible
patient
resulting
from
34


the
investigational
drug,
biological
product,
or
device,
if
35


-4-


LSB
1882XC
(1)
87


tr/nh
4/
6







S.F.
_____


the
manufacturer
or
other
person
or
entity
is
complying
in
1


good
faith
with
the
terms
of
this
chapter
and
has
exercised
2


reasonable
care.
3


2.
This
chapter
shall
not
affect
any
mandatory
health
care
4


coverage
for
participation
in
clinical
trials
under
Title
XIII,
5


subtitle
1.
6


EXPLANATION
7


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
8


the
explanation’s
substance
by
the
members
of
the
general
assembly.
9


This
bill,
titled
the
“Right
to
Try
Act”,
permits
10


manufacturers
of
investigational
drugs,
biological
products,
or
11


devices
to
make
available,
and
eligible
patients
with
terminal
12


illnesses
to
attempt
treatment
with,
an
investigational
13


drug,
biological
product,
or
device
as
long
as
they
provided
14


written
informed
consent.
The
bill
defines
the
terms
“eligible
15


patient”,
“terminal
illness”,
“investigational
drug,
biological
16


product,
or
device”,
and
“written
informed
consent”.
17


Under
the
bill,
an
eligible
patient’s
physician
must
18


acknowledge
that
the
patient’s
illness
is
terminal
and
19


recommend
the
patient
try
an
investigational
drug,
biological
20


product,
or
device.
The
patient’s
written
informed
consent
21


must
acknowledge
that
treatments
currently
approved
by
the
22


United
Stated
food
and
drug
administration
are
unlikely
to
23


prolong
the
patient’s
life.
It
must
identify
the
specific
24


treatment
sought
and
the
potential
best,
worst,
and
expected
25


results
from
the
treatment.
It
must
acknowledge
that
the
26


patient’s
insurance
is
not
required
to
pay
for
the
treatment
27


and
that
any
hospice
service
may
refuse
to
accept
the
patient
28


after
receiving
the
treatment.
It
must
also
acknowledge
29


that
expenses
will
be
credited
to
the
patient,
including
the
30


patient’s
estate,
unless
an
agreement
with
the
manufacturer
of
31


an
investigational
drug,
biological
product,
or
device
states
32


otherwise.
If
the
patient
dies
during
treatment,
the
patient’s
33


heirs
are
not
liable
for
any
remaining
debts
unless
otherwise
34


required
by
law.
35


-5-


LSB
1882XC
(1)
87


tr/nh
5/
6



S.F.
_____


The
manufacturer
of
an
investigational
drug,
biological
1


product,
or
device
may
charge
an
eligible
patient
or
provide
2


the
treatment
free
of
charge.
Governmental
entities
are
3


not
required
to
pay
costs
associated
with
the
use,
care,
4


or
treatment
of
a
patient
with
an
investigational
drug,
5


biological
product,
or
device.
The
bill
does
not
require
6


hospitals
licensed
under
Code
chapter
135B
or
other
health
care
7


facilities
to
provide
new
or
additional
services.
8


Consistent
with
existing
law,
the
board
of
medicine
shall
9


not
take
an
adverse
action
against
a
physician’s
license
solely
10


for
recommending
an
investigational
drug,
biological
product,
11


or
device
for
the
physician’s
eligible
patient.
The
bill
does
12


not
create
a
new
private
cause
of
action
against
any
person
or
13


entity
involved
in
the
care
of
an
eligible
patient
using
the
14


investigational
drug,
biological
product,
or
device
for
any
15


harm
done
to
the
patient
resulting
from
the
treatment
if
the
16


person
or
entity
is
complying
in
good
faith
with
the
terms
of
17


the
bill
and
has
exercised
reasonable
care.
18


-6-


LSB
1882XC
(1)
87


tr/nh
6/
6

